Innovative Oral Biologics Intract Pharma specializes in transforming potent injectable biologics into oral pills, creating a significant market opportunity for pharmaceutical companies seeking patient-friendly delivery formats for complex proteins like monoclonal antibodies.

Strategic Industry Partnerships Their collaborations with biotech and pharmaceutical giants such as Tharimmune, Bio-Thera Solutions, and Celltrion highlight strong industry validation and open doors for licensing and co-development of novel oral biologic therapies, presenting opportunities for licensing or technology integration.

Focus on Gastrointestinal Diseases With a focus on treatments for gastrointestinal and systemic inflammatory diseases, Intract Pharma targets a large, growing patient population, providing potential sales channels for drugs, delivery platforms, and related support services in these therapeutic areas.

Proprietary Technology Platform The company’s Phloral™ and Soteria™ technologies offer distinctive value in oral drug delivery, making them a potential partner or supplier for firms looking to enhance or license advanced biologic delivery solutions.

Early Market Entrant As one of the few companies developing scalable manufacturing processes for oral antibodies and biosimilars, Intract Pharma presents opportunities to engage in manufacturing, supply chain support, and market entry for innovative oral biologic products.